Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure

NCT ID: NCT01544998

Last Updated: 2018-03-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 43 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-02-29
• Study Completion Date: 2014-08-31

Brief Summary

This study is being done to determine the effects of subcutaneous (under the skin) injection of human B-type natriuretic factor (BNP), Natrecor (nesiritide), a hormone produced by the heart, in combination with Tadalafil on:

• The pumping function of the heart
• Kidney function
• Hormonal function (levels of different hormones in your blood) in persons with lower pumping function of their heart.

Detailed Description

In the American Heart Association/American College of Cardiology classification of heart failure (HF), stage B is defined as patients with abnormal heart structure/function (systolic or diastolic dysfunction) without symptoms. This concept of preclinical HF is based on the fact that abnormal heart structure/function can be detected by complementary methods before the development of symptoms. Patients with those abnormalities may progress to heart failure and are at increased risk of adverse cardiac events. Preclinical systolic dysfunction (PSD) is the initial compensated phase of left ventricular systolic dysfunction without symptoms of HF. We have established that diastolic dysfunction is common in the general population being present in approximately 25% of the population over age 45, the majority of whom are asymptomatic i.e., preclinical diastolic dysfunction (PDD). Cyclic guanosine monophosphate (cGMP) is the second messenger of the natriuretic peptide system (NPS) and the nitric oxide system (NO) and plays an important role in the preservation of myocardial, vascular, and renal function. Hence, disruption of this signal transduction process may contribute to the development of cardiorenal dysfunction. Type V phosphodiesterase (PDEV) metabolizes cGMP and is abundant in the kidney, vasculature, and has been recently reported in the heart. We and others have demonstrated that renal PDEV is up-regulated in experimental HF and may lead to the attenuation of renal cGMP generation in response to both endogenous and exogenous BNP, thus serving as a mechanism for renal resistance to BNP. Furthermore, in experimental overt HF, 10 days of PDEV inhibition treatment resulted in reduction of left ventricular (LV) mass, increased LV fractional shortening and cardiac output but did not improve renal function. However, chronic PDEV inhibition did enhance the renal actions of exogenous BNP, specifically improving glomerular filtration rate (GFR) and renal cGMP generation. PDEV inhibitors are FDA approved for erectile dysfunction and pulmonary hypertension.

Conditions

Congestive Heart Failure

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

Tadalafil plus Placebo, then Tadalafil plus Nesiritide

First intervention period: oral Tadalafil; after 1 hour, subcutaneous (sc) placebo given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting. There was a one week washout period. Second intervention period: oral Tadalafil; after 1 hour, sc Nesiritide given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting.

Group Type: EXPERIMENTAL

Nesiritide

Intervention Type: DRUG

10 ug/kg

Tadalafil

Intervention Type: DRUG

5 mg

Placebo

Intervention Type: DRUG

The pharmacy will create a placebo subcutaneous injection volume to match the volume of Nesiritide dose.

Saline load

Intervention Type: DRUG

Normal saline 0.9% 0.25 ml/kg/min for 60 minutes

Tadalafil plus Nesiritide, then Tadalafil plus Placebo

First intervention period: oral Tadalafil; after 1 hour, sc Nesiritide given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting. There was a one week washout period. Second intervention period: oral Tadalafil; after 1 hour, sc placebo given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting.

Group Type: EXPERIMENTAL

Nesiritide

Intervention Type: DRUG

10 ug/kg

Tadalafil

Intervention Type: DRUG

5 mg

Placebo

Intervention Type: DRUG

The pharmacy will create a placebo subcutaneous injection volume to match the volume of Nesiritide dose.

Saline load

Intervention Type: DRUG

Normal saline 0.9% 0.25 ml/kg/min for 60 minutes

Interventions

Nesiritide

10 ug/kg

Intervention Type: DRUG

Tadalafil

5 mg

Intervention Type: DRUG

Placebo

The pharmacy will create a placebo subcutaneous injection volume to match the volume of Nesiritide dose.

Intervention Type: DRUG

Saline load

Normal saline 0.9% 0.25 ml/kg/min for 60 minutes

Intervention Type: DRUG

Other Intervention Names

Cialis; Adcira

Eligibility Criteria

Inclusion Criteria

Group 1 (PSD)

• an ejection fraction of less than 45% with no clinical signs or symptoms of congestive heart failure;
• a minimal distance on 6-minute walk of >450 meters
• calculated creatinine clearance of equal or less than 90 ml/min and greater than 30 ml/min, using the Modification of Diet in Renal Disease (MDRD) formula assessed within the past 24 months. If the creatinine clearance is > 24 months a creatinine test can be drawn at screen/enrollment visit.
• A 6-minute walk distance of 450 meters

Group 2 (PDD)

• ejection fraction of greater than 50% with moderate or severe diastolic dysfunction as assessed by Doppler echocardiography,
• who do not have any signs or symptoms of congestive heart failure
• minimal distance on 6-minute walk of >450 meters
• calculated creatinine clearance of equal or less than 90 ml/min and greater than 30 ml/min

Exclusion Criteria

• Current or anticipated future need for nitrate therapy
• Systolic blood pressure < 90 mmHg or > 180 mm Hg
• Diastolic blood pressure < 40 mmHg or > 100 mmHg
• Resting heart rate (HR) > 100 bpm
• Patients taking alpha antagonists or cytochrome P450 3A4 inhibitors (ketoconazole, itraconazole, erythromycin, saquinavir, cimetidine or serum protease inhibitors for HIV).
• Patients with retinitis pigmentosa, previous diagnosis of nonischemic optic neuropathy, untreated proliferative retinopathy or unexplained visual disturbance
• Patients with sickle cell anemia, multiple myeloma, leukemia or penile deformities placing them at risk for priapism (angulation, cavernosal fibrosis or Peyronie's disease)
• Contraindication to nesiritide.
• Patients with an allergy to iodine.
• Valve disease (> moderate aortic or mitral stenosis; > moderate aortic or mitral regurgitation)
• Hypertrophic cardiomyopathy
• Infiltrative or inflammatory myocardial disease (amyloid, sarcoid)
• Pericardial disease
• Have experienced a myocardial infarction or unstable angina, or have undergone percutaneous transluminal coronary angiography (PTCA) or coronary artery bypass grafting (CABG) within 60 days prior to consent, or requires either PTCA or CABG at the time of consent
• Severe congenital heart diseases
• Sustained ventricular tachycardia or ventricular fibrillation within 14 days of screening
• Second or third degree heart block without a permanent cardiac pacemaker
• Stroke within 3 months of screening or other evidence of significantly compromised central nervous system (CNS) perfusion
• Patients with severe liver disease (AST > 3x normal, alkaline or bilirubin > 2x normal)
• Serum sodium of < 125 milliequivalents (mEq)/dL or > 150 mEq/dL
• Serum potassium of < 3.2 mEq/dL or > 5.7 mEq/dL
• Prior diagnosis of intrinsic renal diseases including renal artery stenosis of > 50%
• Peritoneal or hemodialysis within 90 days or anticipation that dialysis or ultrafiltration of any form will be required during the study period
• Less than 21 years of age
• Pregnant or nursing women.
• Women of child bearing potential who do not have a negative pregnancy test at study entry and who are not using effective contraception

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Center for Research Resources (NCRR)

NIH

Sponsor Role: collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role: collaborator

Mayo Clinic

OTHER

Sponsor Role: lead

Responsible Party

Horng Chen

MD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Horng H Chen, MD

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Mayo Clinic

Rochester, Minnesota, United States

Countries

United States

References

Wan SH, McKie PM, Slusser JP, Burnett JC Jr, Hodge DO, Chen HH. Effects of phosphodiesterase V inhibition alone and in combination with BNP on cardiovascular and renal response to volume load in human preclinical diastolic dysfunction. Physiol Rep. 2021 Aug;9(16):e14974. doi: 10.14814/phy2.14974.

Reference Type: DERIVED

PMID: 34405565 (View on PubMed)

Wan SH, Torres-Courchoud I, McKie PM, Slusser JP, Redfield MM, Burnett JC Jr, Hodge DO, Chen HH. Cardiac Versus Renal Response to Volume Expansion in Preclinical Systolic Dysfunction With PDEV Inhibition and BNP. JACC Basic Transl Sci. 2019 Dec 23;4(8):962-972. doi: 10.1016/j.jacbts.2019.08.008. eCollection 2019 Dec.

Reference Type: DERIVED

PMID: 31909303 (View on PubMed)

Other Identifiers

UL1RR024150

Identifier Type: NIH

Identifier Source: secondary_id

View Link

5P01HL076611

Identifier Type: NIH

Identifier Source: secondary_id

View Link

11-004257

Identifier Type: -

Identifier Source: org_study_id